← Back to codex

17α-Estradiol

Aliases: 17alpha-Estradiol

Last verified: 2026-09-23

Research chemicalPreclinical evidenceSmall moleculesLow interest

The short version

A non-feminizing estradiol stereoisomer — ITP: lifespan extension in male mice (+19%) without feminization; metabolic and immune benefits. Key fact: No controlled human trials exist. Everything known about 17α-Estradiol in humans comes from indirect sources and self-reports. Status: research chemical. Not approved; research chemical.

Identity & type

Molecular type
mali molekul
Origin
A non-feminizing estradiol stereoisomer — ITP: lifespan extension in male mice (+19%) without feminization; metabolic and immune benefits.

Mechanism of action

Acts via ERα with a different profile; reduces inflammation and improves metabolism.

not confirmed in humans

Dosing & routes

Official / clinical context

No approved official document exists for 17α-Estradiol. Any protocols mentioned are to be read as information, not as a recommendation.

Regulator-approved labeling and published study designs — never a recommendation.

Community-reported practice

No human regimens. No human experiences; purely preclinical interest.

Unverified self-reports. Not medical advice. Not endorsement.

Expected effects (community)

No human experiences; purely preclinical interest.

Protocol — official vs community

Official / label

No approved use (pharmaceutical 17α-E2 exists for veterinary indications). ITP male-only lifespan signal drives interest.

Duration: Preclinical only.

The most controversial ITP result: robust male, null female lifespan extension in mice.

Community (anecdotal)

Topical formulations appear in self-experimentation circles; no standardized protocol.

Cycle:
Undefined.
Break:
Undefined.

An unestablished human protocol for an unestablished human indication — the definition of frontier self-experimentation.

Human evidence

No controlled human trials exist. Everything known about 17α-Estradiol in humans comes from indirect sources and self-reports.

Preclinical evidence

ITP preclinical program; no human studies.

Known risks

  • Unknown in humans.characterized

Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.

Unknowns & evidence gaps

  • All human pharmacokinetics, safety and efficacy

Frequently asked questions

References

Systematic references are being expanded; verify sources directly before any decision.